magicmine/iStock via Getty Images
- Insmed Incorporated (NASDAQ:INSM) announced that the U.S. Food and Drug Administration has accepted the company’s New Drug Application for brensocatib for patients with non-cystic fibrosis bronchiectasis.
- In its Day 60 communication to Insmed, the FDA granted Priority Review to the NDA and set a target action date of August 12, 2025, under the Prescription Drug User Fee Act.
- Source: Press Release